Sec Form 4 Filing - Ajer Jeffrey Robert @ BIOMARIN PHARMACEUTICAL INC - 2015-04-30

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Ajer Jeffrey Robert
2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
SVP, Chief Commercial Of
(Last) (First) (Middle)
C/O BIOMARIN PHARMACEUTICAL INC.,, 770 LINDARO ST.
3. Date of Earliest Transaction (MM/DD/YY)
04/30/2015
(Street)
SAN RAFAEL, CA94901
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/30/2015( 1 ) 04/30/2015 A 943 A $ 51.2635 43,033 D
Common Stock 05/06/2015 05/06/2015 M 12,502 A $ 38.59 55,535 D
Common Stock 05/06/2015 05/06/2015 M 625 A $ 21.51 56,160 D
Common Stock 05/06/2015 05/06/2015 M 3,125 A $ 21.51 59,285 D
Common Stock 05/06/2015 05/06/2015 M 2,642 A $ 28.23 61,927 D
Common Stock 05/06/2015 05/06/2015 M 5,258 A $ 28.23 67,185 D
Common Stock 05/06/2015 05/06/2015 M 808 A $ 37.46 67,993 D
Common Stock 05/06/2015 05/06/2015 M 8,671 A $ 37.46 76,664 D
Common Stock 05/06/2015 05/06/2015 S 33,631 D $ 119.1399 ( 2 ) 43,033 D
Common Stock 05/06/2015 05/06/2015 S 388 D $ 119.195 ( 3 ) 42,645 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) Common Stock $ 38.59 05/06/2015 05/06/2015 M 12,502 11/22/2008( 4 ) 05/21/2018 Common Stock 12,502 $ 0 0 ( 5 ) D
Stock Option (right to buy) Common Stock $ 21.51 05/06/2015 05/06/2015 M 625 11/12/2010( 6 ) 11/11/2020 Common Stock 625 $ 0 0 ( 5 ) D
Stock Option (right to buy) Common Stock $ 21.51 05/06/2015 05/06/2015 M 3,125 11/12/2010( 6 ) 11/11/2020 Common Stock 3,125 $ 0 0 ( 5 ) D
Stock Option (right to buy) Common Stock $ 28.23 05/06/2015 05/06/2015 M 2,642 12/01/2011( 7 ) 05/30/2021 Common Stock 2,642 $ 0 978 ( 5 ) D
Stock Option (right to buy) Common Stock $ 28.23 05/06/2015 05/06/2015 M 5,258 12/01/2011( 7 ) 05/30/2021 Common Stock 5,258 $ 0 0 ( 5 ) D
Stock Option (right to buy) Common Stock $ 37.46 05/06/2015 05/06/2015 M 808 11/08/2012 05/07/2022( 7 ) Common Stock 808 $ 0 1,355 ( 5 ) D
Stock Option (right to buy) Common Stock $ 37.46 05/06/2015 05/06/2015 M 8,671 11/08/2012( 8 ) 05/07/2022 Common Stock 8,671 $ 0 2,166 ( 5 ) D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Ajer Jeffrey Robert
C/O BIOMARIN PHARMACEUTICAL INC.,
770 LINDARO ST.
SAN RAFAEL, CA94901
SVP, Chief Commercial Of
Signatures
/s/ Laura Randall Woodhead, Attorney-in-Fact 05/08/2015
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2014 to April 30, 2015.
( 2 )The price in column 4 is an average weighted price. The price actually received ranged from $119.00 to $119.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
( 3 )All shares sold at same price
( 4 )Option grant vests 6/48ths on November 22, 2008, and 1/48th on the 22nd day of every month thereafter.
( 5 )Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
( 6 )Option grant vests 6/48ths on November 12, 2010, and 1/48th on the 12th day of every month thereafter.
( 7 )Option grant vests 6/48ths on December 1, 2011, and 1/48th on the 1st day of every month thereafter.
( 8 )Option grant vests 6/48ths on November 8, 2012, and 1/48th on the 12th day of every month thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.